Technology & Devices

NIH-Led Researchers Develop Software that could Facilitate Drug Development

A team of researchers led by a National Institutes of Health investigator, Teresa Przytycka, Ph.D., has developed a new software tool called AptaTRACE that could be an important advance for drug developers and other scientists who want to identify molecules that bind with high precision to targets of interest. “This …

Read More »

Pfizer and Western Oncolytics Collaborate to Investigate Novel Oncolytic Virus Technology

NEW YORK & CLEVELAND–(BUSINESS WIRE)–Pfizer Inc. (NYSE:PFE) and Western Oncolytics announced today that they have entered into a development collaboration, license and option agreement to advance Western Oncolytics’ novel oncolytic vaccinia virus, WO-12. Oncolytic viruses are viruses engineered to kill cancer cells while sparing healthy cells, which subsequently elicits anti-cancer …

Read More »

Cytox Launches Breakthrough Genetic Biomarker Research Assay for Alzheimer’s Risk Assessment

OXFORD, England–(BUSINESS WIRE)–Cytox Ltd, an innovative developer of assays for risk assessment and prediction of dementia, has announced the launch of its research use variaTECT™ genetic biomarker test for assessing Alzheimer’s disease (AD) risk. The variaTECT™ SNP (single nucleotide polymorphism) array offers a simple blood-based research test providing a comprehensive …

Read More »

FDA Approves Amgen’s Single Monthly Injection for a PCSK9 Inhibitor

THOUSAND OAKS, Calif., July 11, 2016 /PRNewswire/ — Amgen (NASDAQ: AMGN) today announced that the U.S. Food and Drug Administration (FDA) has approved the Repatha® (evolocumab) Pushtronex™ system (on-body infusor with prefilled cartridge), a new, monthly single-dose administration option.1 The Pushtronex system is a hands-free device designed to provide 420 …

Read More »

Castle Biosciences’ Skin Melanoma Gene Expression Test Demonstrates Positive Results

FRIENDSWOOD, Texas–(BUSINESS WIRE)–Castle Biosciences, Inc., a provider of molecular diagnostics to improve cancer treatment decisions, today announced the publication of a prospectively designed, multicenter, decision impact study of its gene expression profile (GEP) test for cutaneous melanoma. The DecisionDx®-Melanoma GEP test accurately predicts metastatic risk independent of current diagnostic modalities …

Read More »

FDA Approves First HPV Test for Use with SurePath Preservative Fluid

The U.S. Food and Drug Administration today approved the Roche cobas HPV Test as the first test for Human Papilloma Virus (HPV) that can be used with cervical cells obtained for a Pap test and collected in SurePath Preservative Fluid. The FDA approves HPV tests to be used with specific …

Read More »

Thermo Fisher Announces Availability of Axiom Precision Medicine Research Array for Screening Initiatives

SANTA CLARA, Calif.–(BUSINESS WIRE)–Epidemiologists and genomics researchers who want to gain a deeper understanding of human genetic variation in translational research now have access to Thermo Fisher Scientific’s Axiom Precision Medicine Research Array, a powerful genotyping solution with more than 900,000 markers of biological significance for clinical research studies. The …

Read More »

CSI Laboratories Launches PD-L1 Expression Assay for Use in Conjunction with Multiple Immunotherapies

ATLANTA–(BUSINESS WIRE)–CSI Laboratories, a private national reference laboratory specializing in cancer diagnostics, announced today the availability of a PD-L1 (programmed death-ligand 1) immunohistochemical (IHC) protein expression assay that can be used to potentially predict a patient’s response to several commercially available PD-1/PD-L1 inhibitor therapies.1 Presently, there are multiple PD-1/PD-L1 inhibitor …

Read More »

E-Consults Increase Access to Specialty Care, Reduce Need for Face-to-Face Appointments

Boston (06/26/16) – According to research presented today at AcademyHealth’s Annual Research Meeting, use by physicians of electronic consultations (e-consults) increases access to specialists’ care for patients who often have the hardest time getting a specialist, including the uninsured, underinsured and those living in rural areas. E-consults leverage electronic health …

Read More »

Epic Sciences’ Liquid Biopsy Test Matches Patients with PARP Inhibitors

SAN DIEGO, June 24, 2016 /PRNewswire/ — Epic Sciences unveiled a liquid biopsy test that more sensitively detects cancers susceptible to PARP inhibitors by targeting homologous recombination deficiency (HRD) in individual circulating tumor cells (CTCs). The new test has already been incorporated into numerous clinical studies of HRD-targeted therapeutics in …

Read More »